Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof

US12018051B2 · kind B2 · utility

Assignee

• The U.S.A., as represented by The Secretary, Department of Health and Human Services · US

Inventors

• Peter L. Collins · Kensington, US
• Bo Liang · Maoming, CN
• Shirin Munir · Bethesda, US
• Anne Schaap Nutt · Austin, US
• Ursula Buchholz · Silver Spring, US
• Natalie Mackow · East Setauket, US
• Peter Kwong · Washington, US
• Barney Graham · Rockville, US
• Jason McLellan · Austin, US

Key dates

• Filing date: Jan 31, 2023
• Grant date: Jun 25, 2024
• Expiry date: Jan 31, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18771
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.